ICON plc — FY2019 Form 20-F Summary
Period: Fiscal year ended December 31, 2019. Although the request specifies 2019 Q4, this filing is an annual report and does not provide a clear standalone fourth-quarter results breakdown. Amounts are in U.S. dollars unless stated otherwise.
Business context and reporting period
ICON is an Ireland-based global contract research organization providing clinical development, laboratory, site and patient recruitment, and commercialization services to pharmaceutical, biotechnology, medical-device, government, and public-health organizations. At year-end it had approximately 14,650 employees across 97 locations in 40 countries. Revenue by region was approximately 31.8% United States, 58.5% Europe, and 9.7% Rest of World.
The statements use U.S. GAAP. FY2019 and FY2018 revenue reflect ASC 606; FY2017 was not restated and is not directly comparable because reimbursable costs were presented differently. ASC 842 lease accounting was adopted in 2019 without restating prior periods.
Financial performance and position
| Metric | FY2019 | FY2018 | Change or context |
|---|---|---|---|
| Revenue | $2,805.8 million | $2,595.8 million | Up 8.1%; 9.6% in constant currency and 8.4% constant-dollar organic growth |
| Operating income | $433.4 million | $373.4 million | Up 16.1%; FY2018 included $12.5 million restructuring charges |
| Operating margin | 15.4% | 14.4% | FY2018 margin was 14.9% excluding restructuring charges |
| Net income attributable to ICON | $374.0 million | $322.7 million | Up approximately 15.9% |
| Basic / diluted EPS | $6.85 / $6.79 | $5.96 / $5.89 | FY2019 GAAP EPS includes a $5.0 million accretion adjustment for MeDiNova’s redeemable noncontrolling interest; adjusted diluted EPS was $6.88 |
| Operating cash flow | $412.5 million | $268.6 million | Increased $143.9 million |
| Cash and cash equivalents | $520.3 million | $395.9 million | Short-term investments were $49.6 million, versus $59.9 million |
| Total assets | $2,907.5 million | $2,354.3 million | Increase includes acquisitions and lease assets |
Direct costs were 70.4% of revenue versus 70.0% in FY2018; SG&A declined to 12.0% of revenue from 12.6%. The effective tax rate rose to 12.0% from 11.5%. Accounts receivable days outstanding increased to 72 from 67, which management attributed in part to extended customer credit terms and collection timing.
Investing cash outflow was $162.0 million, including acquisitions and $50.6 million of capital expenditure. Financing cash outflow was $125.4 million, including $146.9 million of share repurchases. Cash increased by $124.5 million during the year.
Year-end working capital was $493.7 million versus $719.6 million. The filing reports $350 million of Senior Notes, fixed at 3.64% and due December 15, 2020; the balance-sheet carrying amount was approximately $349.6 million and classified as current. The $150 million revolving facility was undrawn. Cash and short-term investments totaled $569.9 million. ICON reported compliance with Senior Note covenants.
Material changes versus the prior comparable period
- Revenue growth reflected organic expansion and the 2019 acquisitions of MolecularMD (MMD), MeDiNova, and Symphony.
- Operating income and margin improved; FY2019 had no restructuring charge compared with $12.5 million in FY2018.
- Operating cash flow increased substantially, while investing outflow rose with acquisition spending.
- Top-five customer concentration declined to 37.6% of revenue from 39.5%, though two customers each contributed over 10% in 2019.
- At year-end, contracted unsatisfied performance obligations were approximately $5.3 billion. ICON expected to recognize about 48% over the next 12 months, but cautioned that projects can be cancelled or delayed.
- ASC 842 adoption added operating right-of-use assets and lease liabilities of $106.5 million at January 1, 2019; FY2019 net operating lease cost was $33.0 million.
Outlook, management commentary, risks, and unusual items
ICON stated that it had adequate liquidity for at least the next 12 months and expected to fund foreseeable needs through operating cash flow, cash balances, and available facilities. It expected to spend approximately $55 million over the next 12 months on information technology, facility expansion, and new offices. The filing does not provide formal revenue or earnings guidance.
Management characterized continued outsourcing by biopharma clients, technology-enabled development, and patient recruitment capabilities as growth opportunities. It also noted that consolidation among sponsors and strategic partnerships with a limited number of CROs affect competition and customer relationships.
- Operational and customer risks: Revenue depends on winning new awards and executing long-term, often fixed-price projects. Cost-estimate errors, unapproved change orders, underutilization, patient or investigator recruitment problems, and customer cancellations or delays may pressure margins and results.
- Concentration and backlog: Two customers each represented more than 10% of revenue. The $5.3 billion performance-obligation balance is not guaranteed revenue and may convert more slowly or be cancelled.
- COVID-19 and other disruption: The filing identifies coronavirus and other disease outbreaks as potential threats to travel, trial monitoring, patient and provider participation, and timely sample processing, while noting significant uncertainty about the potential effect at that time.
- Debt and refinancing: The $350 million Senior Notes mature in December 2020. Management said it was evaluating changes to existing financing or additional financing. The revolving facility uses LIBOR-based pricing, and the filing discusses the scheduled phaseout of LIBOR.
- Acquisitions and contingent payments: ICON acquired MMD, 60% of MeDiNova, and Symphony in 2019. It expected to redeem MeDiNova’s remaining 40% interest for approximately $43.9 million in 2020. Symphony had up to $2.5 million of contingent consideration. MedPass was acquired in January 2020 for initial consideration of $39.2 million.
- Accounting estimates: KPMG identified clinical-trial revenue recognition as a critical audit matter, particularly estimates of costs to complete and realizable contract values. Revenue is recognized over time using project costs, including third-party costs, as an input measure.
- Other exposures: The filing highlights foreign-exchange, privacy and cybersecurity, regulatory-compliance, clinical-trial liability, and international operating risks. It reported no litigation expected to have a material adverse effect.
KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management also concluded that disclosure controls were effective. The filing reports no cash dividends planned for the foreseeable future.
Important facts for investors to verify
- How the December 2020 Senior Notes maturity was refinanced or repaid, and the resulting cost and covenant position.
- Whether the reported revenue growth and margin improvement persisted after 2019, separating organic growth from acquired contributions and currency effects.
- Conversion, timing, and cancellation trends for the $5.3 billion performance-obligation balance, including collection trends given receivables days increased to 72.
- Actual cash paid to acquire MeDiNova’s remaining interest, final contingent consideration for Symphony, and integration results from the 2019 acquisitions and MedPass.
- The operational and financial effects of COVID-19 on clinical-trial activity, recruitment, site operations, and customers.
- Comparability of historical revenue and margins in light of ASC 606’s gross presentation of reimbursable costs and the non-restated FY2017 figures.